M. Southworth, M. Reichman, and E. Unger, Dabigatran and Postmarketing Reports of Bleeding, New England Journal of Medicine, vol.368, issue.14, pp.1272-1276, 2013.
DOI : 10.1056/NEJMp1302834

A. Lambert, Direct oral anticoagulant drugs in elderly patients: Adverse drug events data in France, Les cahiers de l'ann??e g??rontologique, vol.145, issue.3, pp.98-102, 2015.
DOI : 10.1007/s12612-015-0464-4

R. Voelker, Anticoagulant Can Be Reversed, JAMA, vol.314, issue.21, p.2227, 2015.
DOI : 10.1001/jama.2015.16164

F. Dentali, N. Riva, M. Crowther, A. Turpie, G. Lip et al., Efficacy and Safety of the Novel Oral Anticoagulants in Atrial Fibrillation: A Systematic Review and Meta-Analysis of the Literature, Circulation, vol.126, issue.20, pp.2381-91, 2012.
DOI : 10.1161/CIRCULATIONAHA.112.115410

K. Mak, Coronary and mortality risk of novel oral antithrombotic agents: a meta-analysis of large randomised trials, BMJ Open, vol.2, issue.5, 2012.
DOI : 10.1136/bmjopen-2012-001592

C. Coleman, Effect of pharmacological therapies for stroke prevention on major gastrointestinal bleeding in patients with atrial fibrillation, International Journal of Clinical Practice, vol.129, issue.Suppl. 6, pp.53-63, 2012.
DOI : 10.1111/j.1742-1241.2011.02809.x

S. Adam, J. Mcduffie, T. Ortel, and J. Williams, Comparative effectiveness of warfarin and newer oral anticoagulants for the long-term prevention and treatment of arterial and venous thromboembolism

. Washington, DC): Department of Veterans Affairs

D. Capodanno, P. Capranzano, G. Giacchi, V. Calvi, and C. Tamburino, Novel oral anticoagulants versus warfarin in non-valvular atrial fibrillation: A meta-analysis of 50,578 patients, International Journal of Cardiology, vol.167, issue.4, pp.1237-1278, 2013.
DOI : 10.1016/j.ijcard.2012.03.148

C. Miller, S. Grandi, A. Shimony, K. Filion, and M. Eisenberg, Meta-Analysis of Efficacy and Safety of New Oral Anticoagulants (Dabigatran, Rivaroxaban, Apixaban) Versus Warfarin in Patients With Atrial Fibrillation, The American Journal of Cardiology, vol.110, issue.3, pp.453-60, 2012.
DOI : 10.1016/j.amjcard.2012.03.049

G. Ntaios, V. Papavasileiou, H. Diener, K. Makaritsis, and P. Michel, Nonvitamin-K-Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation and Previous Stroke or Transient Ischemic Attack: A Systematic Review and Meta-Analysis of Randomized Controlled Trials fibrillation: A network meta-analysis and indirect comparisons versus dabigatran etexilate, Stroke Thromb Haemost, vol.43104, pp.3298-3041106, 2010.

J. Harenberg, S. Marx, and H. Diener, Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network meta-analysis, Int Angiol, vol.31, pp.330-339, 2012.

L. Rasmussen, T. Larsen, T. Graungaard, F. Skjoth, G. Lip et al., Primary and secondary prevention with new oral anticoagulant drugs for stroke prevention in atrial fibrillation: indirect comparison analysis Systematic review and adjusted indirect comparison meta-analysis of oral anticoagulants in atrial fibrillation, BMJ Circ Cardiovasc Qual Outcomes, vol.345, issue.5, pp.711-720, 2012.

A. Kansal, M. Sharma, C. Bradley-kennedy, A. Clemens, B. Monz et al., Dabigatran versus rivaroxaban for the prevention of stroke and systemic embolism in atrial fibrillation in Canada, Thrombosis and Haemostasis, vol.108, issue.4, pp.672-82, 2012.
DOI : 10.1160/TH12-06-0388

G. Larsen, T. Skjoth, F. Rasmussen, and L. , Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation, J Am Coll Cardiol, vol.60, pp.738-784, 2012.

S. Mantha and A. J. , An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation, Thrombosis and Haemostasis, vol.108, issue.3
DOI : 10.1160/TH12-02-0093

S. Schneeweiss and J. Gagne, Comparative Efficacy and Safety of New Oral Anticoagulants in Patients With Atrial Fibrillation, Circulation: Cardiovascular Quality and Outcomes, vol.5, issue.4, pp.480-486, 2012.
DOI : 10.1161/CIRCOUTCOMES.112.965988

L. Testa, M. Agnifili, R. Latini, R. Mattioli, S. Lanotte et al., Adjusted indirect comparison of new oral anticoagulants for stroke prevention in atrial fibrillation, QJM, vol.105, issue.10, pp.949-57, 2012.
DOI : 10.1093/qjmed/hcs114

. La-poursuite-de-la-thromboprophylaxie-est, recommandée en cas de pose d'une prothèse totale de hanche. Seuls, les HNF et deux HBPM, l'énoxaparine (LOVENOX) et la daltéparine (FRAGMINE) sont indiqués en prévention jusqu'à 35 jours, relais à la thromboprophylaxie court terme par anticoagulant oral (AVK) est aussi envisageable

K. Trois-anticoagulants-oraux-non-antivitamine, NACO) sont actuellement disponibles : lapixaban (ELIQUIS), le rivaroxaban (XARELTO) et le dabigatran (PRADAXA) Les deux premiers sont des inhibiteurs directs du facteur Xa et le troisième est un inhibiteur direct de la thrombine. Tous trois ont été comparés à la warfarine. Ils ont l'AMM en cas de fibrillation auriculaire non valvulaire 83 Les anticoagulants en France en 2014, 2014.

G. Bouvenot, J. Bounhoure, J. Montastruc, and A. Vacheron, Les anticoagulants oraux directs (AOD) (antérieurement appelés « nouveaux anticoagulants oraux » ou NACO) Rapport du 10 juin 2014 pour l'Académie nationale de médecine. 85 Ce rapport se fonde sur des données cliniques d'efficacité et de tolérance, de pharmacovigilance. Il rappelle également les paramètres pharmacocinétiques (voies d'élimination...) et pharmacodynamiques (effet dose-réponse, délai d'action, antagonisation des effets anticoagulants